SensoDetect

Sensodetect AB (publ) today announced a series of strategic initiatives to accelerate its clinical validation program and strengthen the foundation for its AI-driven diagnostic platform. The company is intensifying efforts on its landmark autism spectrum disorder (ASD) study in Saudi Arabia while simultaneously launching broader data collection projects to train its next-generation software.

A key step involves reinforcing the company's presence in the Middle East. To optimize the execution of the Saudi Arabian autism study, Dr. Atwa, Head of Clinical Research, has relocated to Sweden to enhance direct collaboration with the research and development team. This move is complemented by an upcoming visit of CEO, P-A Hedin, to Dubai in early October to engage with regional partners and clinical sites.

"From a clinical perspective, having Dr. Atwa integrated with our core R&D team in Sweden will streamline data analysis and protocol refinement, which is crucial for a high-quality study," said P-A Hedin, CEO of Sensodetect. "From a strategic viewpoint, my visit to the region underscores the immense market potential we see in the Middle East for our tools. We are tackling the study's operational challenges head-on to drive enrollment and generate the robust data set we need."

In parallel, Sensodetect is initiating multiple projects to significantly expand its dataset of neurophysiological data. This large-scale data collection, targeting diverse populations across China, the Middle East, and Europe, is not merely for validation but is fundamental to training more advanced and accurate machine learning algorithms.

This expanded and diverse dataset is a critical corporate asset. It is expected to enhance the algorithm's performance, directly supporting the company's strategy to develop scalable, precise, and clinically valuable diagnostic tools for global neuropsychiatric markets. A larger and more robust dataset also strengthens the company's position for future regulatory submissions.

Sensodetect remains committed to establishing itself as a global leader in medical technology, with a dedicated focus on innovative, objective solutions for neuropsychiatric screening and diagnostics.